Martha Morrell - 27 Feb 2024 Form 4 Insider Report for NeuroPace Inc (NPCE)

Role
Chief Medical Officer
Signature
/s/ Rebecca Kuhn, Attorney-In-Fact
Issuer symbol
NPCE
Transactions as of
27 Feb 2024
Net transactions value
$0
Form type
4
Filing time
28 Feb 2024, 20:56:33 UTC
Previous filing
25 Feb 2025
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NPCE Common Stock Award $0 +12,500 +16% $0.000000 90,262 27 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NPCE Stock Option (Right to Buy) Award $0 +24,950 $0.000000 24,950 27 Feb 2024 Common Stock 24,950 $17.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 27, 2025 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to the option vest on February 27, 2025. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.